MTVA — MetaVia Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1638287 ·
Last close
$1.54
Market Cap
$7.95M
52W High
$4.31
52W Low
$0.97
ADV30
7,631,077
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -4,025,000 | -3,823,000 | 14,388,000 | 13,731,000 | 5,315,000 |
| Dec 2025 | 0 | — | -2,046,000 | -1,930,000 | 11,123,000 | 10,278,000 | 5,790,000 |
| Sep 2025 | 0 | — | -3,475,000 | -3,377,000 | 14,765,000 | 14,277,000 | 8,434,000 |
| Jun 2025 | 0 | — | -4,301,000 | -3,995,000 | 18,459,000 | 17,589,000 | 8,835,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-15,144,000
Investing CF
$-2,000
Financing CF
$17,687,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-9.15
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-152,653,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-13,847,000
Pretax Income TTM
$-13,125,000
Interest Exp TTM
—
Analysts
3
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -13,708,000 | -12,973,000 | 11,123,000 | 5,790,000 | — | -15,701,000 |
| Dec 2024 | 0 | -28,809,000 | -27,592,000 | 16,260,000 | 8,329,000 | — | -24,710,000 |
| Dec 2023 | 0 | -15,886,000 | -12,470,000 | 22,781,000 | 6,096,000 | — | -10,799,000 |
| Dec 2022 | 0 | -11,418,000 | -13,967,000 | 33,534,000 | 11,784,000 | — | -11,712,000 |
| Dec 2021 | — | — | — | — | — | — | — |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ASBP | Aspire Biopharma Holdings, Inc. | $7.99M | $6.17 | — |
| GELS | Gelteq Ltd | $7.84M | $0.73 | — |
| CURX | Curanex Pharmaceuticals Inc | $7.77M | $0.27 | — |
| ADXN | Addex Therapeutics Ltd. | $8.16M | $6.45 | — |
| HCWB | HCW Biologics Inc. | $7.73M | $1.08 | — |
News headlines (Yahoo Finance, 1h cache)
Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th
2026-06-23 12:35 · Yahoo
MTVA: Vanoglipel and DA-1726 Data Presented at ADA 2026 Scientific Sessions
2026-06-17 13:18 · Yahoo
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum
2026-06-17 12:31 · Yahoo
Presenting on Emerging Growth Conference 93 Day 2 on June 11; Register to live stream
2026-06-10 11:00 · Yahoo
BioStem Technologies Announces Appointment of Three New Members to its Board of Directors
2026-06-09 11:00 · Yahoo
MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential
2026-06-08 12:31 · Yahoo
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference
2026-06-04 12:31 · Yahoo
MTVA: No Evidence for Changes in Cardiovascular Parameters in Phase 1 Trial of DA-1726
2026-05-28 10:54 · Yahoo
MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH
2026-05-27 12:31 · Yahoo
MTVA: Multiple Upcoming Presentations to Highlight DA-1726 and Vanoglipel
2026-05-21 13:06 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.